185 related articles for article (PubMed ID: 22898264)
1. Differential expression of miR-21, miR-125b and miR-191 in breast cancer tissue.
Mar-Aguilar F; Luna-Aguirre CM; Moreno-Rocha JC; Araiza-Chávez J; Trevino V; Rodríguez-Padilla C; Reséndez-Pérez D
Asia Pac J Clin Oncol; 2013 Mar; 9(1):53-9. PubMed ID: 22898264
[TBL] [Abstract][Full Text] [Related]
2. Changes in serum levels of miR-21, miR-210, and miR-373 in HER2-positive breast cancer patients undergoing neoadjuvant therapy: a translational research project within the Geparquinto trial.
Müller V; Gade S; Steinbach B; Loibl S; von Minckwitz G; Untch M; Schwedler K; Lübbe K; Schem C; Fasching PA; Mau C; Pantel K; Schwarzenbach H
Breast Cancer Res Treat; 2014 Aug; 147(1):61-8. PubMed ID: 25086636
[TBL] [Abstract][Full Text] [Related]
3. Identification of androgen-responsive microRNAs and androgen-related genes in breast cancer.
Nakano K; Miki Y; Hata S; Ebata A; Takagi K; McNamara KM; Sakurai M; Masuda M; Hirakawa H; Ishida T; Suzuki T; Ohuchi N; Sasano H
Anticancer Res; 2013 Nov; 33(11):4811-9. PubMed ID: 24222117
[TBL] [Abstract][Full Text] [Related]
4. Peripheral blood mammaglobin gene expression for diagnosis and prediction of metastasis in breast cancer patients.
Radwan WM; Moussa HS; Essa ES; Kandil SH; Kamel AM
Asia Pac J Clin Oncol; 2013 Mar; 9(1):66-70. PubMed ID: 22897908
[TBL] [Abstract][Full Text] [Related]
5. MiR-4728-3p could act as a marker of HER2 status.
Li H; Zhou X; Zhu J; Cheng W; Zhu W; Shu Y; Liu P
Cancer Biomark; 2015; 15(6):807-14. PubMed ID: 26406406
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic microRNA markers to screen for sporadic human colon cancer in stool: I. Proof of principle.
Ahmed FE; Ahmed NC; Vos PW; Bonnerup C; Atkins JN; Casey M; Nuovo GJ; Naziri W; Wiley JE; Mota H; Allison RR
Cancer Genomics Proteomics; 2013; 10(3):93-113. PubMed ID: 23741026
[TBL] [Abstract][Full Text] [Related]
7. MicroRNA-132 is frequently down-regulated in ductal carcinoma in situ (DCIS) of breast and acts as a tumor suppressor by inhibiting cell proliferation.
Li S; Meng H; Zhou F; Zhai L; Zhang L; Gu F; Fan Y; Lang R; Fu L; Gu L; Qi L
Pathol Res Pract; 2013 Mar; 209(3):179-83. PubMed ID: 23399321
[TBL] [Abstract][Full Text] [Related]
8. Circulating microRNA-based screening tool for breast cancer.
Frères P; Wenric S; Boukerroucha M; Fasquelle C; Thiry J; Bovy N; Struman I; Geurts P; Collignon J; Schroeder H; Kridelka F; Lifrange E; Jossa V; Bours V; Josse C; Jerusalem G
Oncotarget; 2016 Feb; 7(5):5416-28. PubMed ID: 26734993
[TBL] [Abstract][Full Text] [Related]
9. MiR-183/-96/-182 cluster is up-regulated in most breast cancers and increases cell proliferation and migration.
Li P; Sheng C; Huang L; Zhang H; Huang L; Cheng Z; Zhu Q
Breast Cancer Res; 2014 Nov; 16(6):473. PubMed ID: 25394902
[TBL] [Abstract][Full Text] [Related]
10. Circulating miR-34a and miR-125b as Promising non Invasive Biomarkers in Egyptian Locally Advanced Breast Cancer Patients.
Kassem NM; Makar WS; Kassem HA; Talima S; Tarek M; Hesham H; El-Desouky MA
Asian Pac J Cancer Prev; 2019 Sep; 20(9):2749-2755. PubMed ID: 31554373
[TBL] [Abstract][Full Text] [Related]
11. Negligible nuclear FOXP3 expression in breast cancer epithelial cells compared with FOXP3-positive T cells.
Droeser RA; Obermann EC; Wolf AM; Wallner S; Wolf D; Tzankov A
Clin Breast Cancer; 2013 Aug; 13(4):264-70. PubMed ID: 23829892
[TBL] [Abstract][Full Text] [Related]
12. DNA methylation contributes to deregulation of 12 cancer-associated microRNAs and breast cancer progression.
Pronina IV; Loginov VI; Burdennyy AM; Fridman MV; Senchenko VN; Kazubskaya TP; Kushlinskii NE; Dmitriev AA; Braga EA
Gene; 2017 Mar; 604():1-8. PubMed ID: 27998789
[TBL] [Abstract][Full Text] [Related]
13. Tumor-suppressive microRNA-34a inhibits breast cancer cell migration and invasion via targeting oncogenic TPD52.
Li G; Yao L; Zhang J; Li X; Dang S; Zeng K; Zhou Y; Gao F
Tumour Biol; 2016 Jun; 37(6):7481-91. PubMed ID: 26678891
[TBL] [Abstract][Full Text] [Related]
14. The mRNA expression of inhibitors of DNA binding-1 and -2 is associated with advanced tumour stage and adverse clinical outcome in human breast cancer.
Wazir U; Jiang WG; Sharma AK; Newbold RF; Mokbel K
Anticancer Res; 2013 May; 33(5):2179-83. PubMed ID: 23645773
[TBL] [Abstract][Full Text] [Related]
15. Epigenetic inactivation of microRNA gene hsa-mir-9-1 in human breast cancer.
Lehmann U; Hasemeier B; Christgen M; Müller M; Römermann D; Länger F; Kreipe H
J Pathol; 2008 Jan; 214(1):17-24. PubMed ID: 17948228
[TBL] [Abstract][Full Text] [Related]
16. MiR-142-3p as a potential prognostic biomarker for esophageal squamous cell carcinoma.
Lin RJ; Xiao DW; Liao LD; Chen T; Xie ZF; Huang WZ; Wang WS; Jiang TF; Wu BL; Li EM; Xu LY
J Surg Oncol; 2012 Feb; 105(2):175-82. PubMed ID: 21882196
[TBL] [Abstract][Full Text] [Related]
17. A novel tumor suppressor gene RhoBTB2 (DBC2): frequent loss of expression in sporadic breast cancer.
Mao H; Qu X; Yang Y; Zuo W; Bi Y; Zhou C; Yin H; Deng B; Sun J; Zhang L
Mol Carcinog; 2010 Mar; 49(3):283-9. PubMed ID: 19937980
[TBL] [Abstract][Full Text] [Related]
18. Breast cancer prognosis determined by gene expression profiling: a quantitative reverse transcriptase polymerase chain reaction study.
Espinosa E; Vara JA; Redondo A; Sánchez JJ; Hardisson D; Zamora P; Pastrana FG; Cejas P; Martínez B; Suárez A; Calero F; Barón MG
J Clin Oncol; 2005 Oct; 23(29):7278-85. PubMed ID: 16129846
[TBL] [Abstract][Full Text] [Related]
19. Overexpression of caveolin-1 and -2 in cell lines and in human samples of inflammatory breast cancer.
Van den Eynden GG; Van Laere SJ; Van der Auwera I; Merajver SD; Van Marck EA; van Dam P; Vermeulen PB; Dirix LY; van Golen KL
Breast Cancer Res Treat; 2006 Feb; 95(3):219-28. PubMed ID: 16244790
[TBL] [Abstract][Full Text] [Related]
20. miRNA expression profiles of oral squamous cell carcinomas.
Gombos K; Horváth R; Szele E; Juhász K; Gocze K; Somlai K; Pajkos G; Ember I; Olasz L
Anticancer Res; 2013 Apr; 33(4):1511-7. PubMed ID: 23564792
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
